论文部分内容阅读
目的:检测慢性乙型肝炎(CHB)患者外周血浆中细胞因子IL-18、IP-10水平在抗病毒治疗过程中不同时期的水平,并探讨其临床意义。方法:用双抗体夹心ELISA法定量检测33例CHB患者抗病毒治疗不同时期的血浆IL-18、IP-10水平,并同时检测其肝功能。结果:抗病毒治疗后,血浆IL-18、IP-10及血清ALT水平有明显的下降,治疗后第12周、第24周与治疗前比较差别均有统计学意义(P<0.05),且IL-18、IP-10与ALT呈正相关(r分别为0.269、0.656,P值分别为P<0.05、P<0.01)。结论:IL-18、IP-10在慢乙肝患者肝脏免疫损伤中发挥重要作用,监测抗病毒治疗过程中血浆IL-18、IP-10水平变化有助于了解机体免疫动态,评价抗病毒药物疗效。
Objective: To detect the levels of cytokines IL-18 and IP-10 in peripheral blood of patients with chronic hepatitis B (CHB) during different stages of antiviral therapy and to explore its clinical significance. Methods: The levels of plasma IL-18 and IP-10 in 33 patients with CHB were detected by double-antibody sandwich ELISA. The liver function was also tested. Results: The levels of plasma IL-18, IP-10 and serum ALT decreased significantly after antiviral treatment. The difference between the 12th week and the 24th week after treatment was statistically significant (P <0.05), and IL-18 and IP-10 were positively correlated with ALT (r = 0.269,0.656, P <0.05 respectively, P <0.01). Conclusion: IL-18 and IP-10 play an important role in liver injury in patients with chronic hepatitis B. Monitoring the changes of plasma IL-18 and IP-10 during antiviral therapy may help to understand the immune dynamics and evaluate the efficacy of antiviral drugs .